Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI)

Authors: Fei Ji, Yao Liang, Shun-Jun Fu, Zhi-Yong Guo, Man Shu, Shun-Li Shen, Shao-Qiang Li, Bao-Gang Peng, Li-Jian Liang, Yun-Peng Hua

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

The occurrence and development of hepatocellular carcinoma (HCC) depends largely on such non-tumor factors as inflammatory condition, immune state, viral infection and liver fibrosis. Various inflammation-based prognostic scores have been associated with survival in patients with HCC, such as the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR) and the prognostic nutritional index (PNI). The aspartate aminotransferase/platelet count ratio index (APRI) is thought to be a biomarker of liver fibrosis and cirrhosis. This study aims to evaluate the ability of these indices to predict survival in HCC patients after curative hepatectomy, and probe the increased prognostic accuracy of APRI combined with established inflammation-based prognostic scores.

Methods

Data were collected retrospectively from 321 patients who underwent curative resection for HCC. Preoperative NLR, PLR, PNI, APRI and clinico-pathological variables were analyzed. Univariate and multivariate analyses were performed to identify the predictive value of the above factors for disease-free survival (DFS) and overall survival (OS).

Results

Univariate analysis showed that NLR, PLR, PNI and APRI were significantly associated with DFS and OS in HCC patients with curative resection. Multivariate analysis showed that NLR and APRI were superior to PLR and PNI, and both were independently correlated with DFS and OS. Preoperative NLR >2 or APRI >1.68 predicted poor prognosis of patients with HCC after hepatectomy. Furthermore, the predictive range of NLR combined with APRI was more sensitive than that of either measure alone.

Conclusions

Preoperative NLR and APRI are independent predictors of DFS and OS in patients with HCC after surgical resection. Higher levels of NLR or APRI predict poorer outcomes in HCC patients. Intriguingly, combining NLR and APRI increases the prognostic accuracy of testing.
Literature
1.
El–Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.CrossRefPubMed
2.
Ji F, Fu S-J, Shen S-L, Zhang L-J, Cao Q-H, Li S-Q, et al. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma. BMC Cancer. 2015;15(1):116.PubMedCentralCrossRefPubMed
3.
Abdelgawad IA. Clinical utility of simple non-invasive liver fibrosis indices for predicting hepatocellular carcinoma (HCC) among Egyptian patients. J Clin Pathol. 2015;68(2):154–60.CrossRefPubMed
4.
Mano Y, Shirabe K, Yamashita Y-i, Harimoto N, Tsujita E, Takeishi K, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–5.CrossRefPubMed
5.
Pinato D, North B, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439–45.PubMedCentralCrossRefPubMed
6.
Lai KP, Chen J, He M, Ching AK, Lau C, Lai P, et al. Overexpression of ZFX confers self‐renewal and chemoresistance properties in hepatocellular carcinoma. Int J Cancer. 2014;135(8):1790–9.CrossRefPubMed
7.
Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res. 2011;185:135-48.
8.
Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, Chan HL, To K-F. Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. Ann Surg Oncol. 2015;22(13):4138-48
9.
Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil‐to‐lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553–61.CrossRefPubMed
10.
Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64.CrossRefPubMed
11.
Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, et al. Pretreatment neutrophil–lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine. 2015;94(11):e639.PubMedCentralCrossRefPubMed
12.
Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L. Platelet-tolymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumor Biol. 2015;36(4):2263-9
13.
Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, et al. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2015;30(1):131–8.PubMedCentralCrossRefPubMed
14.
Shen S-L, Fu S-J, Chen B, Kuang M, Li S-Q, Hua Y-P, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol. 2014;21(12):3802–9.CrossRefPubMed
15.
Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1407–32.CrossRefPubMed
16.
Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC): TNM classification of malignant tumours. 7th edn. New York: Wiley-Liss; 2010
17.
Schütte K, Tippelt B, Schulz C, Röhl FW, Feneberg A, Seidensticker R, Arend J, Malfertheiner P. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr. 2015;34(6):1122-7
18.
Gomez D, Farid S, Malik H, Young A, Toogood G, Lodge J, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32(8):1757–62.CrossRefPubMed
19.
Halazun KJ, Hardy MA, Rana AA, Woodland IV DC, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–51.CrossRefPubMed
20.
Huang Z-L, Luo J, Chen M-S, Li J-Q, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2011;22(5):702–9.CrossRefPubMed
21.
Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.PubMed
22.
Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg. 2015;39(6):1501–9.CrossRefPubMed
23.
Xue TC, Jia QA, Ge NL, Zhang BH, Wang YH, Ren ZG, Ye SL. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumor Biol. 2015;36(8):6045-51
24.
Xia W, Ke Q, Wang Y, Wang W, Zhang M, Shen Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol. 2015;13(1):60.PubMedCentralCrossRefPubMed
25.
Wu J-C, Huang Y-H, Chau G-Y, Su C-W, Lai C-R, Lee P-C, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–7.CrossRefPubMed
26.
Hung H-H, Su C-W, Lai C-R, Chau G-Y, Chan C-C, Huang Y-H, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4(4):691–9.PubMedCentralCrossRefPubMed
27.
Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25(4):428–34.PubMed
28.
Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard‐Hubert I, et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40(2):178–88.CrossRefPubMed
29.
Kao W-Y, Chiou Y-Y, Hung H-H, Chou Y-H, Su C-W, Wu J-C, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase–platelet ratio index. Eur J Gastroenterol Hepatol. 2011;23(6):528–36.PubMed
30.
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–61.CrossRefPubMed
Metadata
Title
A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI)
Authors
Fei Ji
Yao Liang
Shun-Jun Fu
Zhi-Yong Guo
Man Shu
Shun-Li Shen
Shao-Qiang Li
Bao-Gang Peng
Li-Jian Liang
Yun-Peng Hua
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2189-1

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Study protocol

ColoNav: patient navigation for colorectal cancer screening in deprived areas – Study protocol

Debate

Insulin-like growth factor-1 signaling in renal cell carcinoma

Research article

Changes in the in vitro activity of platinum drugs when administered in two aliquots

Research article

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy

Research article

Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells

Research article

MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits